These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38720945)

  • 1. Case Report: Efficacy, safety, and favorable long-term outcome of early treatment with IL-1 inhibitors in a patient with chronic infantile neurological cutaneous articular (CINCA) syndrome caused by NLRP3 mosaicism.
    Costagliola G; D'Elios S; Cappelli S; Massei F; Maestrini G; Beni A; Peroni D; Consolini R
    Front Pediatr; 2024; 12():1379616. PubMed ID: 38720945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Infantile Neurological Cutaneous and Articular (CINCA) syndrome: a review.
    Finetti M; Omenetti A; Federici S; Caorsi R; Gattorno M
    Orphanet J Rare Dis; 2016 Dec; 11(1):167. PubMed ID: 27927236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
    Neven B; Marvillet I; Terrada C; Ferster A; Boddaert N; Couloignier V; Pinto G; Pagnier A; Bodemer C; Bodaghi B; Tardieu M; Prieur AM; Quartier P
    Arthritis Rheum; 2010 Jan; 62(1):258-67. PubMed ID: 20039428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A somatic NLRP3 mutation as a cause of a sporadic case of chronic infantile neurologic, cutaneous, articular syndrome/neonatal-onset multisystem inflammatory disease: Novel evidence of the role of low-level mosaicism as the pathophysiologic mechanism underlying mendelian inherited diseases.
    Aróstegui JI; Lopez Saldaña MD; Pascal M; Clemente D; Aymerich M; Balaguer F; Goel A; Fournier del Castillo C; Rius J; Plaza S; López Robledillo JC; Juan M; Ibañez M; Yagüe J
    Arthritis Rheum; 2010 Apr; 62(4):1158-66. PubMed ID: 20131270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes.
    Nakagawa K; Gonzalez-Roca E; Souto A; Kawai T; Umebayashi H; Campistol JM; Cañellas J; Takei S; Kobayashi N; Callejas-Rubio JL; Ortego-Centeno N; Ruiz-Ortiz E; Rius F; Anton J; Iglesias E; Jimenez-Treviño S; Vargas C; Fernandez-Martin J; Calvo I; Hernández-Rodríguez J; Mendez M; Dordal MT; Basagaña M; Bujan S; Yashiro M; Kubota T; Koike R; Akuta N; Shimoyama K; Iwata N; Saito MK; Ohara O; Kambe N; Yasumi T; Izawa K; Kawai T; Heike T; Yagüe J; Nishikomori R; Aróstegui JI
    Ann Rheum Dis; 2015 Mar; 74(3):603-10. PubMed ID: 24326009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study.
    Tanaka N; Izawa K; Saito MK; Sakuma M; Oshima K; Ohara O; Nishikomori R; Morimoto T; Kambe N; Goldbach-Mansky R; Aksentijevich I; de Saint Basile G; Neven B; van Gijn M; Frenkel J; Aróstegui JI; Yagüe J; Merino R; Ibañez M; Pontillo A; Takada H; Imagawa T; Kawai T; Yasumi T; Nakahata T; Heike T
    Arthritis Rheum; 2011 Nov; 63(11):3625-32. PubMed ID: 21702021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful management of cryopyrin-associated periodic syndrome with canakinumab in infancy.
    Kanariou M; Tantou S; Varela I; Raptaki M; Petropoulou C; Nikas I; Valari M
    Pediatrics; 2014 Nov; 134(5):e1468-73. PubMed ID: 25349319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.
    Caorsi R; Lepore L; Zulian F; Alessio M; Stabile A; Insalaco A; Finetti M; Battagliese A; Martini G; Bibalo C; Martini A; Gattorno M
    Arthritis Res Ther; 2013 Feb; 15(1):R33. PubMed ID: 23442610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cryopyrin-associated periodic syndromes].
    Quartier P; Rodrigues F; Georgin-Lavialle S
    Rev Med Interne; 2018 Apr; 39(4):287-296. PubMed ID: 29111302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of cryopyrin-associated periodic syndrome: challenges, recommendations and emerging concepts.
    Sarrabay G; Grandemange S; Touitou I
    Expert Rev Clin Immunol; 2015; 11(7):827-35. PubMed ID: 25979514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
    Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
    Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cryopyrin-associated periodic syndrome].
    Kümmerle-Deschner JB
    Z Rheumatol; 2012 Apr; 71(3):199-208. PubMed ID: 22527214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
    Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
    Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap).
    Church LD; Savic S; McDermott MF
    Biologics; 2008 Dec; 2(4):733-42. PubMed ID: 19707454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resolution of femoral metaphyseal dysplasia in CINCA syndrome after long-term treatment with interleukin-1 blockade.
    Rigante D; Manna R; Verrecchia E; Marrocco R; Leone A
    Clin Rheumatol; 2018 Jul; 37(7):2007-2009. PubMed ID: 29766377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neonatal treatment of CINCA syndrome.
    Paccaud Y; Berthet G; Von Scheven-Gête A; Vaudaux B; Mivelaz Y; Hofer M; Roth-Kleiner M
    Pediatr Rheumatol Online J; 2014; 12():52. PubMed ID: 25584041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cochlear implantation in a child with CINCA syndrome who also has wide vestibular aqueducts.
    Bates JE; Bruce IA; Henderson L; Melling C; Green KM
    Cochlear Implants Int; 2012 Aug; 13(3):173-6. PubMed ID: 22333493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians.
    Kuemmerle-Deschner JB; Haug I
    Ther Adv Musculoskelet Dis; 2013 Dec; 5(6):315-29. PubMed ID: 24294305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAPS--pathogenesis, presentation and treatment of an autoinflammatory disease.
    Kuemmerle-Deschner JB
    Semin Immunopathol; 2015 Jul; 37(4):377-85. PubMed ID: 25963520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early progression of atherosclerosis in children with chronic infantile neurological cutaneous and articular syndrome.
    Yamamura K; Takada H; Uike K; Nakashima Y; Hirata Y; Nagata H; Takimoto T; Ishimura M; Morihana E; Ohga S; Hara T
    Rheumatology (Oxford); 2014 Oct; 53(10):1783-7. PubMed ID: 24821850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.